Genentech (RHHBY) Announces Significant Data from TECENTRIQ Phase 3 Data in Specific Lung Cancer

Clovis Oncology (CLVS) Announces Presentation of Encouraging Efficacy, Safety Data on Rucaparib in BRCA Ovarian Cancer

Clovis Oncology (Nasdaq: CLVS) announced the oral presentation of the primary efficacy and safety data from its NDA dataset for rucaparib at the 2016 ESMO Congress in Copenhagen. Rucaparib is currently under priority review with FDA for the monotherapy treatment of advanced ovarian cancer in patients with BRCA-mutated tumors inclusive of both germline and somatic BRCA mutations who have been treated with two or more chemotherapies, and the submission has a PDUFA date of February 23, 2017.

Rucaparib is the Companys oral, small molecule inhibitor of PARP1, PARP2 and PARP3 currently being developed for the... More

Exelixis (EXEL) Announces Presentation of Cobimetinib, Vemurafenib, Atezolizumab Combo Phase 1b Data in BRAF V600

Exelixis, Inc. (Nasdaq: EXEL) announced that its collaborator Genentech, a member of the Roche Group (OTC: RHHBY), will present preliminary results from a phase 1b clinical trial evaluating the safety and clinical activity of the triple combination of cobimetinib, vemurafenib, and atezolizumab in patients with previously untreated BRAF V600 mutation-positive advanced melanoma. The results will be the subject of a poster discussion presentation (Abstract #1109PD) at the European Society of Medical Oncology (ESMO) 2016 Congress, which is being held October 7-11 in Copenhagen, Denmark. Patrick Hwu, M.D.,... More

Exelixis (EXEL) Announces Encouraging Cabozantinib Combo Phase 1 Data in Genitourinary Tumors

Exelixis, Inc. (Nasdaq: EXEL) announced results from a phase 1 trial of cabozantinib in combination with nivolumab in patients with previously treated genitourinary tumors. The findings will be presented during a poster discussion session (Abstract #774PD) on October 9 at the European Society for Medical Oncology (ESMO) 2016 Congress, which is being held in Copenhagen, October 7 11, 2016.

The treatment landscape for advanced, intractable cancers such as metastatic urothelial carcinoma is continuously evolving and the use of combination therapies may improve outcomes for patients in need of new options, said Andrea Apolo, M.D., Genitourinary Malignancies Branch, Center for Cancer... More

Kite Pharma (KITE) Commences KTE-C19 Combo Phase 1b/2 Combination Study in DLBCL (RHHBY)

Kite Pharma, Inc. (Nasdaq: KITE) announced the first patient was enrolled in ZUMA-6, a Phase 1b/2 clinical study of KTE-C19 in combination with atezolizumab, Genentechs anti-PD-L1 cancer immunotherapy. The trial is designed to evaluate the safety and efficacy of the combination in patients with refractory diffuse large B-cell lymphoma (DLBCL).

PD-L1 expression in DLBCL is associated with high-risk disease and poor outcomes. The interaction of PD-L1 and PD-1, which is expressed on KTE-C19, may dampen T-cell activity in some... More